AMRX Amneal Pharmaceuticals Inc. Class A

Amneal to Report Third Quarter 2023 Results on November 7, 2023

BRIDGEWATER, N.J.--(BUSINESS WIRE)--

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2023 financial results on Tuesday, November 7, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time.

The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at .

Individuals may register for the conference call by clicking the link . Once registered, participants will receive dial-in details and unique PIN which will allow them to access the call.

To access the call through a conference line, dial 1 (833) 470-1428 (in the U.S.) or for a list of toll-free international numbers, visit this . The access code for the call is 605508.

A replay of the conference call will be posted shortly after the call and will be available for seven days.

About Amneal

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully integrated global pharmaceuticals company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of approximately 270 pharmaceutical products, primarily within the United States. In its Generics segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit .

EN
05/10/2023

Underlying

AMRXAmneal Pharmaceuticals Inc. Class A

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Amneal Pharmaceuticals Inc. Class A

 PRESS RELEASE
Free
AMRX Amneal Pharmace...

Amneal Pharmaceuticals Added to S&P SmallCap 600® Index

Amneal Pharmaceuticals Added to S&P SmallCap 600® Index BRIDGEWATER, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has been added to the S&P SmallCap 600® Index. The inclusion will become effective prior to the opening of trading on Friday, January 30, 2026. Launched in 1994, the S&P SmallCap 600 Index is one of the most widely followed benchmarks for U.S. small-capitalization equities. The index is commonly used by active managers and small-cap investors seeking exposure to companies that meet disc...

January 28, 2026 1 EN
 PRESS RELEASE
Free
AMRX Amneal Pharmace...

Amneal to Report Fourth Quarter and Full Year 2025 Results on February...

Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026 BRIDGEWATER, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced that the Company will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at . Individuals may register for the webcast by clickin...

January 27, 2026 1 EN
 PRESS RELEASE
Free
AMRX Amneal Pharmace...

Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Pro...

Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA® Approvals expand Amneal’s biosimilars portfolioCompany expects to commercialize six biosimilars across eight presentations by 2027 BRIDGEWATER, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, today announced that the U.S. Food and Drug Administration (FDA) has approved its Biologics Licensing Applications (BLAs) for Boncresa™ (denosumab-mobz), a b...

December 22, 2025 1 EN
 PRESS RELEASE
Free
AMRX Amneal Pharmace...

Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single-...

Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals Expands Amneal’s injectables portfolio with an essential medicine used in hospitals for emergency and perioperative care BRIDGEWATER, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s epinephrine injection USP, 1 mg/mL (1 mL), in single-dose vials and 1 mg/mL (30 mL) multi-dose vials. This medicine is a critical therapy utilize...

December 9, 2025 1 EN
 PRESS RELEASE
Free
AMRX Amneal Pharmace...

Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREX...

Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease Interim data show substantial improvements in “Good On” time compared to other oral CD/LD therapiesCREXONT delivered substantial “Off” time reductions, improved motor symptom control and provided a longer duration of benefit with each doseFindings highlight CREXONT as a key therapy in a category with limited innovationELEVATE-PD study is ongoing with longer-term data expected in 2026 BRIDGEWATER, N.J., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”...

December 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch